Recent News for EDIT - Editas Medicine, Inc.

Date Title
Nov 20 Editas Medicine (EDIT) in Focus: Stock Moves 7.8% Higher
Nov 20 Vertex, CRISPR's Gene Editing Drug Shows Positive Early Data
Nov 20 The NASDAQ Needs No Break
Nov 19 CRISPR Therapeutics stock jumps on early gene editing data
Nov 13 Editas adds to Celgene collaboration-stoked up move, shares ahead 4%
Nov 13 Editas (EDIT) Beats on Q3 Earnings, Amends Celgene Deal
Nov 12 Edited Transcript of EDIT earnings conference call or presentation 12-Nov-19 1:00pm GMT
Nov 12 Editas Medicine, Inc. (EDIT) CEO Cindy Collins on Q3 2019 Results Earnings Call - Transcript
Nov 12 Editas Medicine, Inc. 2019 Q3 - Results - Earnings Call Presentation
Nov 12 Editas Medicine +5% on Q3 results
Nov 12 Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates
Nov 12 The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat
Nov 12 Editas Medicine EPS beats by $0.06, misses on revenue
Nov 12 Editas Medicine Announces Third Quarter 2019 Results and Update
Nov 12 Editas Medicine and Celgene Corporation Amend Existing Collaboration to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for the Treatment of Cancer and Autoimmune Diseases
Nov 11 Notable earnings before Tuesday’s open
Nov 11 Editas Medicine Q3 2019 Earnings Preview
Nov 5 Editas Medicine to Host Conference Call Discussing Third Quarter 2019 Results and Corporate Update
Nov 1 Editas Medicine In The Realm Of Designer Humans
Oct 31 8 Undervalued Biotech Stocks to Watch Now
Oct 30 Analysts Estimate Editas Medicine (EDIT) to Report a Decline in Earnings: What to Look Out for
Oct 29 Experts Talk Hot Biotech Stocks at Barron’s Breakfast
Oct 28 Editas Medicine Appoints Judith R. Abrams, M.D., as Chief Medical Officer
Oct 28 Is Editas Medicine, Inc. (EDIT) Going to Burn These Hedge Funds?
Oct 28 CRISPR Therapeutics up 5% on advancement of key programs & collaborations
Back to the Main EDIT Page...